Compare PRK & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRK | CLDX |
|---|---|---|
| Founded | 1908 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 1996 | 1995 |
| Metric | PRK | CLDX |
|---|---|---|
| Price | $184.58 | $38.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $184.00 | $46.60 |
| AVG Volume (30 Days) | 102.5K | ★ 1.3M |
| Earning Date | 04-24-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $664,421,000.00 | $12,743,000.00 |
| Revenue This Year | $24.26 | $111.39 |
| Revenue Next Year | $3.63 | $235.85 |
| P/E Ratio | $76.51 | ★ N/A |
| Revenue Growth | 2.92 | ★ 87.78 |
| 52 Week Low | $149.06 | $19.72 |
| 52 Week High | $188.04 | $40.30 |
| Indicator | PRK | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 69.27 |
| Support Level | $165.30 | $28.51 |
| Resistance Level | $188.04 | N/A |
| Average True Range (ATR) | 3.73 | 1.70 |
| MACD | -0.10 | 0.41 |
| Stochastic Oscillator | 73.62 | 82.71 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.